Loading...
OTCM
MDGEF
Market cap10mUSD
, Last price  
USD
Name

Medigene AG

Chart & Performance

D1W1MN
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
0.74%
Rev. gr., 5y
-4.89%
Revenues
6m
-80.69%
31,224,00023,877,00039,606,00039,466,0002,292,0004,656,0006,284,0007,592,00013,784,0006,808,0009,749,00011,375,0007,754,00010,632,0008,749,00010,463,00031,247,0006,034,000
Net income
-16m
L+94.20%
-6,891,000-29,876,000-30,790,000-21,962,000-17,869,0006,281,000-9,859,000-10,282,000-5,757,000-12,999,000-9,492,000-13,573,000-17,049,000-19,962,000-28,875,000-9,983,000-8,330,000-16,177,000
CFO
-15m
L
-1,266,000-32,043,000-27,361,000-18,925,000-11,411,0006,864,000-6,507,000-12,246,000-8,756,000-10,605,000-3,758,000-20,849,000-10,142,000-16,423,000-24,786,000-10,754,00011,976,000-15,119,000
Earnings
Apr 24, 2025

Profile

Medigene AG, a biotechnology company, focuses on the development of T cell immunotherapies for the treatment of cancer. The company is developing personalized T cell-based therapies with a focus on T cell receptor-modified T cells in the areas of unmet medical needs, which are in clinical development. It also focuses on dendritic cell vaccines and T cell-specific monoclonal antibodies. In addition, the company focuses on developing and marketing RhuDex for hepatology and gastroenterology indications. Medigene AG has a strategic partnership with 2seventy bio, Inc. for the development of T cell receptors. The company also has research collaboration agreements on novel cancer antigens for immunotherapies with the Université de Montréal; and with Cytovant Sciences Co. Ltd. It has operations in Europe, the United States, Asia, and internationally. The company was founded in 1994 and is headquartered in Munich, Germany.
URL
https://www.medigene.de/
IPO date
Jun 30, 2000
Employees
87
Domiciled in
DE
Incorporated in
DE

Valuation

Title
EUR in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
6,034
-80.69%
31,247
198.64%
Cost of revenue
17,499
35,555
Unusual Expense (Income)
NOPBT
(11,465)
(4,308)
NOPBT Margin
Operating Taxes
(415)
(1,044)
Tax Rate
NOPAT
(11,050)
(3,264)
Net income
(16,177)
94.20%
(8,330)
-16.56%
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
914
980
Long-term debt
4,986
6,472
Deferred revenue
427
3,622
Other long-term liabilities
368
579
Net debt
(10,774)
(25,772)
Cash flow
Cash from operating activities
(15,119)
11,976
CAPEX
(664)
(1,007)
Cash from investing activities
2,384
(12,005)
Cash from financing activities
(776)
(282)
FCF
(10,096)
(2,752)
Balance
Cash
16,674
33,224
Long term investments
Excess cash
16,372
31,662
Stockholders' equity
(459,179)
(442,911)
Invested Capital
483,990
486,676
ROIC
ROCE
EV
Common stock shares outstanding
24,563
24,563
Price
Market cap
EV
EBITDA
(10,002)
17,544
EV/EBITDA
Interest
548
659
Interest/NOPBT